Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Corcept Therapeutics (CORT) over the last 9 years, with Q3 2025 value amounting to $296.5 million.

  • Corcept Therapeutics' Short-term Investments rose 2201.14% to $296.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.5 million, marking a year-over-year increase of 2201.14%. This contributed to the annual value of $255.7 million for FY2024, which is 988.48% up from last year.
  • Corcept Therapeutics' Short-term Investments amounted to $296.5 million in Q3 2025, which was up 2201.14% from $239.5 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Short-term Investments high stood at $365.3 million for Q4 2022, and its period low was $145.9 million during Q4 2021.
  • For the 5-year period, Corcept Therapeutics' Short-term Investments averaged around $265.4 million, with its median value being $261.0 million (2024).
  • As far as peak fluctuations go, Corcept Therapeutics' Short-term Investments tumbled by 5996.83% in 2021, and later soared by 15037.56% in 2022.
  • Over the past 5 years, Corcept Therapeutics' Short-term Investments (Quarter) stood at $145.9 million in 2021, then surged by 150.38% to $365.3 million in 2022, then plummeted by 36.31% to $232.7 million in 2023, then grew by 9.88% to $255.7 million in 2024, then increased by 15.99% to $296.5 million in 2025.
  • Its last three reported values are $296.5 million in Q3 2025, $239.5 million for Q2 2025, and $232.9 million during Q1 2025.